Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by IVERIC bio, Inc.
< Previous
1
2
Next >
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2023
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 02, 2023
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 24, 2023
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
Astellas Enters Into Definitive Agreement to Acquire Iveric Bio
April 30, 2023
From
IVERIC Bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio Announces New Functional Vision Loss Reduction Data from Avacincaptad Pegol GATHER Trials Presented at ARVO Annual Meeting
April 23, 2023
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2023
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 02, 2023
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio Reports Fourth Quarter and Full Year 2022 Operational Highlights and Financial Results
March 01, 2023
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio to Present at the Cowen 43rd Annual Health Care Conference
February 28, 2023
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on Wednesday, March 1, 2023
February 22, 2023
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio Announces FDA Accepts New Drug Application and Grants Priority Review for Avacincaptad Pegol for the Treatment of Geographic Atrophy
February 16, 2023
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2023
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 04, 2023
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directors
January 03, 2023
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy
December 20, 2022
From
Iveric bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 02, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio Announces Pricing of $300 Million Public Offering of Common Stock
November 30, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio Announces Proposed Offering of Common Stock
November 30, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy
November 17, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy
November 03, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio Reports Third Quarter 2022 Operational Highlights and Financial Results
November 03, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 02, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio to Report Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 3, 2022
October 27, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio to Present Top-line Results for Avacincaptad Pegol from Phase 3 GATHER2 Clinical Trial in Geographic Atrophy at AAO 2022 Annual Meeting
September 27, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio to Present at Upcoming Investor Conferences
September 07, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio Announces Positive Topline Data from Zimura® GATHER2 Phase 3 Clinical Trial in Geographic Atrophy
September 06, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio to Participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
August 10, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
Iveric Bio to Present at the Wedbush PacGrow Healthcare Conference 2022
August 03, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Tickers
ISEE
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.